Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?  

Given how favorable the results of Keynote 905/EV-303 appear to be, would you extrapolate this for bladder preservation?  Would you use it as "neoadjuvant" prior to definitive chemoRT?